Polygon Therapeutics

Polygon Therapeutics is a pioneering French startup in cardioimmunology that aims to develop an innovative biomedicine to improve the acute management of myocardial infarction.

Polygon Therapeutics has developed a monoclonal antibody that targets the immune system to prevent heart damage in ischemic cardiovascular disease. The startup aims to significantly improve outcomes in myocardial infarction and cardiovascular disease.